glp-1 efficacy and safety of LY3298176, a novel dual GIP and receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial GLP-1 Orals and Multi-Agonists: Advancing

Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, et al

Staying informed through resources like SeekPeptides ensures you have access to the latest evidence as the field evolves

Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturers direct-to-patient expansion to date

Rowell, J

The researchers assessed total GLP-1, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and the Global Registry of Acute Coronary Events (GRACE) score in 918 patients presenting with myocardial infarction [321 ST-segment elevation myocardial infarction and 597 non-ST-segment elevation myocardial infarction (NSTEMI)] at the time of hospital admission

Build muscle through strength training